NVCT
Nuvectis Q3 2026 results and in-licensing announcement
Nuvectis reports Q3 2026 financial results and details the in-licensing of two drugs, ciprocopan and NXP200, while awaiting FDA updates before year-end.
NVCT news
Latest 4 stories · newest Nov 4, 2026
NVCT
NVCT
Nuvectis in-licenses late-stage oncology drugs and raises $115M in follow-on offering to fund pipeline expansion
Nuvectis acquired ex-China rights to oncology assets NXP100 and NXP200 and closed a $115M July 2026 follow-on offering with cash runway extending into 1H 2029.
NVCT
Nuvectis Agrees to License Drug Assets from Haisco
Nuvectis Pharma expands its pipeline by licensing ex-China rights for NXP100 and NXP200 from Haisco Pharmaceutical Group. This strategic acquisition of two clinical-stage assets aims to strengthen the company's focus on complement-mediated diseases and oncology.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same NVCT feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/NVCT/newsSTART FREE